SCHEMBL30765996

SCHEMBL30765996

CCCCOC(=O)Cn1c(N2CCCCC2)ncc(N[C@H](C)c2ccc(-c3ccccc3)s2)c1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.41
POLB P06746 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
GAA P10253 1/20 0.41
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
LMNA P02545 4/20 0.37
ALDH1A1 P00352 3/20 0.37
TSHR P16473 4/20 0.36
NPSR1 Q6W5P4 3/20 0.36
THRB P10828 1/20 0.34
MAPK1 P28482 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
KDM4E B2RXH2 1/20 0.34
HSD17B10 Q99714 1/20 0.34
ADORA1 P30542 1/20 0.34
IDH1 O75874 1/20 0.34
AVPR1B P47901 2/20 0.33
TP53 P04637 2/20 0.33
NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765622 0.87 IDH1 (0.38) ALDH1A1NPSR1IDH1NPC1ELANE
SCHEMBL30765475 0.87 ALDH1A1 (0.36) LMNAALDH1A1TSHRNPSR1KDM4E
SCHEMBL31558496 0.86 IDH1 (0.37) MAPTKMT2AMEN1ALDH1A1NPSR1
SCHEMBL30765811 0.84 L3MBTL1 (0.41) MAPTPOLBL3MBTL1GAAKMT2A
SCHEMBL30765621 0.83 GAA (0.42) MAPTPOLBL3MBTL1GAAKMT2A
SCHEMBL30766040 0.77 F2 (0.36) MAPK1IDH1
SCHEMBL30765509 0.76 LMNA (0.43) MAPTPOLBL3MBTL1GAAKMT2A
SCHEMBL30765616 0.76 LMNA (0.37) MAPTPOLBL3MBTL1GAAKMT2A
SCHEMBL30765532 0.73 GAA (0.53) MAPTPOLBL3MBTL1GAAKMT2A
SCHEMBL30765514 0.72 ALDH1A1 (0.48) MAPTPOLBL3MBTL1GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed